tiprankstipranks
Organogenesis backs FY25 revenue view $480M-$535M, consensus $549.3M
PremiumThe FlyOrganogenesis backs FY25 revenue view $480M-$535M, consensus $549.3M
1M ago
CMS reviewing coverage policies for skin substitute products
Premium
The Fly
CMS reviewing coverage policies for skin substitute products
2M ago
Organogenesis Highlights Strategic Focus in Investor Presentation
Premium
Company Announcements
Organogenesis Highlights Strategic Focus in Investor Presentation
3M ago
Organogenesis Holdings Reports Strong Q4 2024 Results
PremiumCompany AnnouncementsOrganogenesis Holdings Reports Strong Q4 2024 Results
4M ago
Organogenesis sees FY25 revenue $480M-$535M, consensus $472.94M
Premium
The Fly
Organogenesis sees FY25 revenue $480M-$535M, consensus $472.94M
4M ago
Organogenesis reports Q4 EPS 4c, consensus 2c
Premium
The Fly
Organogenesis reports Q4 EPS 4c, consensus 2c
4M ago
Organogenesis Holdings Secures $130M Investment for Growth
PremiumCompany AnnouncementsOrganogenesis Holdings Secures $130M Investment for Growth
7M ago
Organogenesis Reports Robust Third Quarter Growth
Premium
Company Announcements
Organogenesis Reports Robust Third Quarter Growth
7M ago
Organogenesis reports Q3 EPS 9c, consensus (1c)
Premium
The Fly
Organogenesis reports Q3 EPS 9c, consensus (1c)
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100